Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing In Vitro Fertilization (IVF)

Sponsor
Reproductive Medicine Associates of New Jersey (Other)
Overall Status
Completed
CT.gov ID
NCT01219504
Collaborator
(none)
200
3
53
66.7
1.3

Study Details

Study Description

Brief Summary

To assess the impact of embryo biopsy on the reproductive potential of human embryos.

Detailed Description

This study will recruit patients from the NY/NJ/CT/eastern PA area only.

All patients will undergo an in vitro fertilization (IVF) cycle with hormonal stimulation and an egg retrieval procedure as deemed appropriate for their diagnosis. Following biopsy, the embryos will be transferred. There will be no delay in the time of transfer as no cells will be analyzed prior to transfer.

On day 3 or day 5 of embryo development, all patients will undergo a two (2) embryo transfer. The embryos selected for transfer will be the 2 morphologically best of the embryo cohort. Once selected for transfer, the embryos will be randomized so that one will be biopsied and the other will be transferred without undergoing biopsy. The embryo randomized to biopsy will have a single cell biopsied.

Following delivery, buccal swabs will be collected from infants.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Time Perspective:
Prospective
Official Title:
Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing IVF
Study Start Date :
Apr 1, 2008
Actual Primary Completion Date :
Sep 1, 2012
Actual Study Completion Date :
Sep 1, 2012

Outcome Measures

Primary Outcome Measures

  1. Impact of biopsy on pregnancy [1 year]

    Impact of the biopsy of the embryo on whether a pregnancy is obtained

  2. Impact of biopsy on delivery [1 year]

    Impact of the biopsy on pregnancy resulting in delivery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

This study will recruit patients from the NY/NJ/CT/eastern PA area only.

Inclusion Criteria:
  1. Maximum of one prior failed IVF treatment cycle

  2. Female partner less than 35 years of age

  3. Normal day 3 FSH level (<10 miu/mL)

  4. Total basal antral follicle count greater than or equal to 12

  5. Male partner with greater than 100,000 total motile spermatozoa and at least 1% normal forms

  6. Body mass index (BMI) < or = 32

  7. Normal uterine cavity

Exclusion Criteria:
  1. Diagnosis of chronic anovulation secondary to polycystic ovarian disease

  2. Diagnosis of endometrial insufficiency

  3. Clinical indication for pre-implantation genetic diagnosis (PGD) (undergoing IVF with PGD to rule out a known genetic defect)

  4. Use of testicular aspiration or biopsy procedures to obtain sperm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Reproductive Medicine Associates of Connecticut Norfolk Connecticut United States 06850
2 Reproductive Medicine Associates of New Jersey Morristown New Jersey United States 07960
3 Reproductive Medicine Associates of New York New York New Jersey United States 10022

Sponsors and Collaborators

  • Reproductive Medicine Associates of New Jersey

Investigators

  • Principal Investigator: Richard T Scott, MD, Reproductive Medicine Associates of New Jersey

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Reproductive Medicine Associates of New Jersey
ClinicalTrials.gov Identifier:
NCT01219504
Other Study ID Numbers:
  • RMA-00-17
First Posted:
Oct 13, 2010
Last Update Posted:
Jan 23, 2013
Last Verified:
Jan 1, 2013
Keywords provided by Reproductive Medicine Associates of New Jersey

Study Results

No Results Posted as of Jan 23, 2013